Consorcio Hospitalario Provincial De Castellon
- Address
- lock Available on a paid plan
Male Urogenital Cancers
The Medical Oncology department at Consorcio Hospitalario Provincial De Castellon concentrates on advanced prostate cancer research, aiming to improve survival and quality of life for men with resistant disease.
- Castration‑Resistant Prostate Cancer
- Metastatic hormone‑sensitive prostate cancer
- High‑risk NM‑CRPC
- Bone‑dominant metastatic prostate disease
Ongoing studies compare standard chemotherapy with targeted radiopharmaceuticals such as Radium‑223, evaluate next‑generation androgen‑axis inhibitors like Apalutamide, and assess novel combination regimens to delay disease progression.
Solid Tumor Oncology
Across a broad spectrum of neoplasms, the site conducts trials that test new targeted therapies, immunotherapies, and precision‑medicine approaches to enhance outcomes for patients with breast, ovarian, and lymphoid cancers.
- Breast Cancer (HR‑positive/HER2‑negative, HER2‑positive, Triple‑Negative)
- Ovarian and fallopian tube cancer
- Diffuse Large B‑Cell Lymphoma
- Follicular Lymphoma
- Pancreatic adenocarcinoma with CLDN18.2 expression
Trials evaluate combinations such as olaparib with immunotherapy, compare antibody‑drug conjugates like Trastuzumab Deruxtecan versus T‑DM1, and test adjuvant PARP inhibition to reduce invasive disease‑free recurrence in high‑risk breast cancer.
Lung Cancer & Respiratory Oncology
The department’s respiratory research targets both non‑small‑cell and small‑cell lung cancers, focusing on novel immuno‑oncology agents and strategies to overcome resistance and brain metastases.
- Non‑Small Cell Lung Cancer (NSCLC)
- Small Cell Lung Cancer
- NSCLC with brain metastasis
- PD‑L1‑high metastatic NSCLC
- Urothelial carcinoma with lung involvement
Current studies assess the benefit of adding tiragolumab to checkpoint inhibition, compare novel PD‑L1 blockers such as durvalumab plus chemotherapy, and explore maintenance immunotherapy after chemoradiation in unresectable disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 87 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 85 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 15 by active trials.
- 1AstraZeneca AB2active
lock +14 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB5trials
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Consorcio Hospitalario Provincial De Castellon
lock Showing 1 of 44 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2 clinical trial of Pembrolizumab in combination with Carboplatin and Cabazitaxel in Aggressive Variant Metastatic Castration Resistant Prostate Cancer | Fundacion Oncosur | Phase II | Not Recruiting | May 2023 | Jun 2026 |
IMP list
lock Showing 1 of 87 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 8 | Unknown | 2017-07-06 | 2026-05-18 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.